Dashboard PDUFA PDUFA History Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free public preview Track VRTX with free AI briefings, catalyst countdowns, and dilution alerts.

VRTX

FDA catalysts, PDUFA dates with approval probability, drug pipeline, cash runway and insider activity — updated automatically from SEC, FDA and ClinicalTrials.gov data.

$6.1B Cash on Hand

CF+ Cash Runway

1.8% Short Interest

🧪 Upcoming Trial Catalysts

2027-01-01 · Phase 2 — Active Trial — Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17
2027-04-06 · Phase 3 — Recruiting — Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic P
2027-05-31 · Phase 3 — Recruiting — Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Periphe
2027-06-01 · Phase 3 — Active Trial — Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle
2028-06-02 · Phase 2, Phase 3 — Recruiting — Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated
2028-07-01 · Phase 2, Phase 3 — Active Trial — Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Tre

💰 Cash Runway & Dilution Risk

VRTX holds $6.1B in cash and its operations are currently cash-flow neutral or positive.

Source: SEC EDGAR XBRL (operating cash flow). Get dilution alerts for VRTX free →

📈 Recent Insider Activity (Form 4)

Date	Insider	Type	Value
2026-07-23	Sachdev Amit	Purchase	$0
2026-07-23	Tatsis Ourania	Purchase	$0
2026-07-17	SACHS BRUCE I	Purchase	$7.5M
2026-07-17	Garber Alan M	Purchase	$30,893
2026-07-07	Tatsis Ourania	Sale	$23.8M

Get the full VRTX picture

A free BioRadar account adds AI daily briefings, sentiment tracking, trial enrollment progress, and email alerts for VRTX and 2 more tickers of your choice.

Create Free Account →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z